AmeriHealth Caritas Next | FirstChoice Next
A Product of Select Health of South Carolina, Inc.

Provider Alerts

Important information for our Next providers.

To: **AmeriHealth Caritas Next and First Choice Next Providers**

Date: **October 2, 2024**

Subject: Pfizer Voluntarily Withdraws All Lots of Sickle Cell Disease Treatment OXBRYTA® (voxelotor) From Worldwide Markets

On Wednesday, September 25th, Pfizer Inc. announced that it is voluntarily withdrawing all lots of OXBRYTA ® (voxelotor) for the treatment of sickle cell disease (SCD), in all markets where it is approved. Pfizer is also discontinuing all active voxelotor clinical trials and expanded access programs worldwide.

According to a press release issued by Pfizer on September 25, its decision is based on the totality of clinical data that now indicates the overall benefit of OXBRYTA no longer outweighs the risk in the approved sickle cell patient population. The data suggest an imbalance in vaso-occlusive crises and fatal events which require further assessment. Pfizer has notified regulatory authorities about these findings and its decision to voluntarily withdraw OXBRYTA from the market and discontinue distribution and clinical studies while further reviewing the available data and investigating the findings.

Patients, physicians, pharmacists, or other healthcare professionals with additional questions about OXBRYTA should contact Pfizer Medical Information 1-800-438-1985.

Effective immediately, no future prescription claims for OXBRYTA will be able to be processed and no prior authorization requests for OXBRYTA will be approved. AmeriHealth Caritas Next and FirstChoice Next will contact all members who have filled a prescription for OXBRYTA as well as their prescribers to notify them of the market withdrawal and that they will not be able to continue to obtain OXBRYTA from the pharmacy.

Please see the link below for more details.
https://www.pfizer.com/news/press-release/press-release-detail/pfizer-voluntarily-withdraws-all-lots-sickle-cell-disease